Citi Predicts Up to 410% Rally for These 2 ‘Strong Buy’ Stocks
With the third quarter well underway and most second-quarter earnings now in the rearview mirror, investors are starting to look ahead to the rest ...
Syndax Pharmaceuticals Inc (SNDX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Kynam Capital Derrick Tang | 8,050,959 | $175,993,964 | 9.73% | |
| 2. | Deerfield Management James E. Flynn | 3,779,900 | $82,628,614 | 0.86% | |
| 3. | Eversept Partners Kamran Moghtaderi | 2,798,210 | $61,168,871 | -4% | 3.17% |
| 4. | Hood River Capital Management David Swank | 2,564,279 | $56,055,139 | +9% | 0.41% |
| 5. | Kingdon Capital Mark Kingdon | 2,500,000 | $54,650,000 | 5.6% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.00 | 3,000 | $0.00 | 93,746 | 2025-05-19 | Filing | |
| $9.00 | 11,765 | $105,826.18 | 35,165 | 2025-05-16 | Filing | |
| $8.99 | 5,000 | $44,950.00 | 79,000 | 2025-05-19 | Filing | |
| $9.11 | 10,000 | $91,120.00 | 100,000 | 2025-05-19 | Filing | |
| $20.03 | 1,250 | $25,037.25 | 52,623 | 2024-06-14 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $24.24 | 32,375 | $784,776.48 | 484,843 | 2026-07-08 | Filing | |
| $18.14 | 31,235 | $566,602.90 | 60,885 | 2026-06-12 | Filing | |
| $18.00 | 34,280 | $617,040.00 | 60,885 | 2026-06-11 | Filing | |
| $18.99 | 1,177 | $22,351.23 | 139,252 | 2026-06-01 | Filing | |
| $18.99 | 6,847 | $130,024.53 | 484,843 | 2026-06-01 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 9,020,006 | $197,177,353 | 0% | |
| 2. | 5,861,265 | $128,127,253 | 0.01% | |
| 3. | 5,658,424 | $123,693,149 | 0% | |
| 4. | 4,045,094 | $88,425,755 | 0.01% | |
| 5. | 3,927,892 | $85,863,719 | 0% |
News See All
Is Syndax Pharmaceuticals, Inc. (SNDX) Stock Still a Biotech Opportunity After Revised AML Market Estimates?
We recently compiled a list of the 10 Most Promising Cancer Stocks According to Wall Street Analysts. Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) is one of the most promising stocks on our list.
10 Most Promising Cancer Stocks According to Wall Street Analysts
In this article, we will be taking a look at the 10 Most Promising Cancer Stocks According to Wall Street Analysts.
Why Syndax Pharmaceuticals (SNDX) is One of the Best Small Cap Stocks to Buy for 10x Potential
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) is one of the best small cap stocks to buy for 10x potential. On May 4, Stifel lifted the price target on Syndax Pharmaceuticals, Inc.
15 Best Small Cap Stocks to Buy for 10x Potential
In this article, we will look at the 15 Best Small Cap Stocks to Buy for 10x Potential.
Syndax Pharmaceuticals Inc. (SNDX) on a Strong Footing amid Robust Demand for Key Flagship Drugs
Syndax Pharmaceuticals (NASDAQ:SNDX) is one of the best cancer stocks to invest in now.
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q4 2025 Earnings Call Transcript
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q4 2025 Earnings Call Transcript February 26, 2026 Operator: Good day, everyone, and welcome to the Syndax Fourth Quarter 2025 Earnings Conference Call.
11 Best Cancer Stocks to Invest In Now
In this article, we will discuss the 11 Best Cancer Stocks to Invest In Now. Pharmaceutical companies are a blend of defensive income plays and growth opportunities.
BofA Raised Syndax (SNDX) PT to $28, Cites Heavy Pre-Announcements Lowering Earnings Impact
Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) is one of the most promising low-cost stocks to buy now.
11 Most Promising Low-Cost Stocks to Buy Now
On February 7, Richard Bernstein, CEO of Richard Bernstein Advisors, joined 'The Exchange' on CNBC to discuss the state of equity markets, assessing which stocks are growing fast and trading cheaply.
Hedge Fund Resource Center